Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGR-hTNF in Advanced HCC
NCT00484211Phase 2Completed
- Sponsor
- AGC Biologics
- Start
- Dec 2006
- Primary completion
- Nov 2011
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NGR-TNF in hepatocellular carcinoma (HCC), sponsored by AGC Biologics. Primary endpoint: Progression Free Survival. Started Dec 2006; status: completed.
02
Drugs
NGR-TNF
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00484211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00484211.